ISLB 2026

Date: November 7, 2026 - November 9, 2026
Type: In-person
Location: Europe
Areas of Interest: Oncology

Join SOPHiA GENETICS at the International Society for Liquid Biopsy Annual Meeting (ISLB) 2026 in Madrid, Spain. Find us at Booth #28, where we are excited to connect with the liquid biopsy community and share how our technology expands precision oncology capabilities.

Explore our latest innovations, including new MSK-ACCESS® powered with SOPHiA DDM™ capabilities for ctDNA fraction measurement and MSI detection.

Stop by our booth to meet our product, commercial, and technical experts and discover what’s next for SOPHiA DDM™. Check out our full program below.

Industry Symposium

Monday, 9 November 2026 | 11:30pm – 12:30pm | Room Tapices

"Expanding the genomic landscape with liquid biopsy: Insights from decentralizing MSK-ACCESS®"

Speakers:

Alex Charles Tuck, Ph.D – VP, Genomic Research, SOPHiA GENETICS
Federico Rojo – Head of Pathology Department, Fundación Jiménez Díaz University Hospital

In this session, our speakers will discuss the role and value of matched tumor-normal sequencing in liquid biopsy and how it can support accurate interpretation of cfDNA findings. They will also share practical insights from the real-world deployment of MSK-ACCESS® powered with SOPHiA DDM™ at Fundación Jiménez Díaz. A light lunch will be provided.

Add to Calendar

Stakeholder Workshop

Saturday, 7 November 2026 | 2:35pm – 3:15pm | Room Tapices

"Translational Science in Liquid Biopsy"

Join Kevin Puylaert, Chief Sales Officer at SOPHiA GENETICS, as he shares insights as a panelist in the Stakeholder Workshop on Translational Science in Liquid Biopsy.

Add to Calendar

Meet the Experts Networking Session

Saturday, 7 November 2026 | 3:15pm – 4:00pm | Booth #28

You are cordially invited to our Meet the Experts Networking Session! Join us for an opportunity to connect and engage in conversation with our experts and learn more about the latest innovations on the SOPHiA DDM™ Platform.

Add to Calendar

Book a Meeting

Name

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Company(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

Job Title/Industry(Required)

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services